Treace Launches HyperPlate™ XM Implant for Midfoot Surgery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Technological Innovation: Treace successfully completed the first surgery using the HyperPlate™ XM Dynamic Compression Locking Implant, which incorporates FastPitch® locking screws to enhance insertion speed and dynamic compression, thereby improving stability and strength in midfoot and hindfoot surgeries.
- Market Expansion: The launch of the HyperPlate™ XM implant signifies Treace's ongoing expansion in the foot and ankle market, expected to drive increased procedural utilization and deepen customer engagement and market share.
- Clinical Feedback: Dr. Paul Dayton from the Foot & Ankle Center noted that the HyperPlate™ XM implant performed exceptionally well in large joint fusion surgeries, significantly improving insertion efficiency and joint preparation, indicating a potential increase in surgical success rates.
- Commercialization Plan: Treace anticipates full commercialization of the HyperPlate™ XM implant and its suite of sterile instruments in the third quarter of 2026, further solidifying its leadership position in the foot medical technology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMCI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMCI
Wall Street analysts forecast TMCI stock price to rise
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 4.010
Low
3.00
Averages
4.87
High
7.50
Current: 4.010
Low
3.00
Averages
4.87
High
7.50
About TMCI
Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Treace Launches HyperPlate™ XM Implant for Midfoot Surgery
- Technological Innovation: Treace successfully completed the first surgery using the HyperPlate™ XM Dynamic Compression Locking Implant, which incorporates FastPitch® locking screws to enhance insertion speed and dynamic compression, thereby improving stability and strength in midfoot and hindfoot surgeries.
- Market Expansion: The launch of the HyperPlate™ XM implant signifies Treace's ongoing expansion in the foot and ankle market, expected to drive increased procedural utilization and deepen customer engagement and market share.
- Clinical Feedback: Dr. Paul Dayton from the Foot & Ankle Center noted that the HyperPlate™ XM implant performed exceptionally well in large joint fusion surgeries, significantly improving insertion efficiency and joint preparation, indicating a potential increase in surgical success rates.
- Commercialization Plan: Treace anticipates full commercialization of the HyperPlate™ XM implant and its suite of sterile instruments in the third quarter of 2026, further solidifying its leadership position in the foot medical technology sector.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Treace Medical (TMCI) Q4 2025 Earnings Transcript
See More
Treace Medical (TMCI) Q1 2026 Earnings Transcript
See More
Treace Medical Concepts Q1 2026 Earnings Call Insights
- Revenue Decline: Treace Medical reported Q1 2026 revenue of $47.2 million, reflecting a 10% year-over-year decline, with expectations that this trend will improve as new products launched in 2025 begin to annualize, impacting overall revenue performance.
- Full-Year Revenue Guidance: The company reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, anticipating continued revenue declines until the fourth quarter, but expects growth to return driven by increased case volumes and new product launches.
- New Product Commercialization: Full commercialization of SuperBite and SpeedXM is expected in Q3 2026, collectively expanding the total addressable market by approximately $300 million, thereby enhancing the company's competitive position in the foot and ankle market.
- Adjusted EBITDA Loss: The company anticipates an adjusted EBITDA loss ranging from $4 million to $6 million for 2026, while also expecting a 50% reduction in cash usage compared to 2025, indicating a focus on cost control.
See More
Treace Medical Q1 Earnings Beat Expectations
- Earnings Highlights: Treace Medical Concepts reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in a loss position.
- Revenue Performance: The company generated $47.2 million in revenue for Q1, a 10.3% year-over-year decline, yet it exceeded expectations by $1.15 million, demonstrating resilience in sales amid market challenges.
- Gross Profit and Margin: Gross profit for Q1 was $37.4 million, down from $41.9 million in Q1 2025, with gross margin slightly decreasing from 79.7% to 79.3%, reflecting cost pressures impacting profitability.
- Operating Expense Control: Total operating expenses for Q1 were $54.6 million, a decrease of $2.9 million compared to the same period last year, showcasing effective cost management measures that contribute to improving overall financial health.
See More
Treace Launches HyperPlate™ XM Implant for Midfoot Surgery
- Technological Innovation: Treace successfully completed the first surgery using the HyperPlate™ XM Dynamic Compression Locking Implant, which incorporates FastPitch® locking screws to enhance insertion speed and dynamic compression, thereby improving stability and strength in midfoot and hindfoot surgeries.
- Market Expansion: The launch of the HyperPlate™ XM implant signifies Treace's ongoing expansion in the foot and ankle market, expected to drive increased procedural utilization and deepen customer engagement and market share.
- Clinical Feedback: Dr. Paul Dayton from the Foot & Ankle Center noted that the HyperPlate™ XM implant performed exceptionally well in large joint fusion surgeries, significantly improving insertion efficiency and joint preparation, indicating a potential increase in surgical success rates.
- Commercialization Plan: Treace anticipates full commercialization of the HyperPlate™ XM implant and its suite of sterile instruments in the third quarter of 2026, further solidifying its leadership position in the foot medical technology sector.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Treace Medical (TMCI) Q4 2025 Earnings Transcript
See More
Treace Medical (TMCI) Q1 2026 Earnings Transcript
See More
Treace Medical Concepts Q1 2026 Earnings Call Insights
- Revenue Decline: Treace Medical reported Q1 2026 revenue of $47.2 million, reflecting a 10% year-over-year decline, with expectations that this trend will improve as new products launched in 2025 begin to annualize, impacting overall revenue performance.
- Full-Year Revenue Guidance: The company reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, anticipating continued revenue declines until the fourth quarter, but expects growth to return driven by increased case volumes and new product launches.
- New Product Commercialization: Full commercialization of SuperBite and SpeedXM is expected in Q3 2026, collectively expanding the total addressable market by approximately $300 million, thereby enhancing the company's competitive position in the foot and ankle market.
- Adjusted EBITDA Loss: The company anticipates an adjusted EBITDA loss ranging from $4 million to $6 million for 2026, while also expecting a 50% reduction in cash usage compared to 2025, indicating a focus on cost control.
See More
Treace Medical Q1 Earnings Beat Expectations
- Earnings Highlights: Treace Medical Concepts reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in a loss position.
- Revenue Performance: The company generated $47.2 million in revenue for Q1, a 10.3% year-over-year decline, yet it exceeded expectations by $1.15 million, demonstrating resilience in sales amid market challenges.
- Gross Profit and Margin: Gross profit for Q1 was $37.4 million, down from $41.9 million in Q1 2025, with gross margin slightly decreasing from 79.7% to 79.3%, reflecting cost pressures impacting profitability.
- Operating Expense Control: Total operating expenses for Q1 were $54.6 million, a decrease of $2.9 million compared to the same period last year, showcasing effective cost management measures that contribute to improving overall financial health.
See More
